Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $9.28 billion. The enterprise value is $9.56 billion.
| Market Cap | 9.28B |
| Enterprise Value | 9.56B |
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Aug 18, 2025 |
Share Statistics
Bio-Techne has 155.69 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 155.69M |
| Shares Outstanding | 155.69M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | -2.01% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | 102.93% |
| Float | 153.85M |
Valuation Ratios
The trailing PE ratio is 129.52 and the forward PE ratio is 29.78. Bio-Techne's PEG ratio is 3.04.
| PE Ratio | 129.52 |
| Forward PE | 29.78 |
| PS Ratio | 7.70 |
| Forward PS | 7.29 |
| PB Ratio | 4.81 |
| P/TBV Ratio | 16.21 |
| P/FCF Ratio | 36.16 |
| P/OCF Ratio | 32.26 |
| PEG Ratio | 3.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.86, with an EV/FCF ratio of 37.26.
| EV / Earnings | 130.28 |
| EV / Sales | 7.84 |
| EV / EBITDA | 28.86 |
| EV / EBIT | 36.04 |
| EV / FCF | 37.26 |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.46 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.25 |
| Debt / FCF | 1.73 |
| Interest Coverage | 31.17 |
Financial Efficiency
Return on equity (ROE) is 3.68% and return on invested capital (ROIC) is 6.83%.
| Return on Equity (ROE) | 3.68% |
| Return on Assets (ROA) | 6.30% |
| Return on Invested Capital (ROIC) | 6.83% |
| Return on Capital Employed (ROCE) | 11.14% |
| Revenue Per Employee | $393,431 |
| Profits Per Employee | $23,665 |
| Employee Count | 3,100 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, Bio-Techne has paid $25.06 million in taxes.
| Income Tax | 25.06M |
| Effective Tax Rate | 25.45% |
Stock Price Statistics
The stock price has decreased by -19.29% in the last 52 weeks. The beta is 1.48, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -19.29% |
| 50-Day Moving Average | 54.75 |
| 200-Day Moving Average | 57.45 |
| Relative Strength Index (RSI) | 58.48 |
| Average Volume (20 Days) | 2,695,214 |
Short Selling Information
The latest short interest is 5.38 million, so 3.46% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short Previous Month | 5.27M |
| Short % of Shares Out | 3.46% |
| Short % of Float | 3.50% |
| Short Ratio (days to cover) | 2.19 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $73.36 million in profits. Earnings per share was $0.46.
| Revenue | 1.22B |
| Gross Profit | 811.12M |
| Operating Income | 265.24M |
| Pretax Income | 98.46M |
| Net Income | 73.36M |
| EBITDA | 331.14M |
| EBIT | 265.24M |
| Earnings Per Share (EPS) | $0.46 |
Balance Sheet
The company has $162.19 million in cash and $444.06 million in debt, giving a net cash position of -$281.87 million or -$1.81 per share.
| Cash & Cash Equivalents | 162.19M |
| Total Debt | 444.06M |
| Net Cash | -281.87M |
| Net Cash Per Share | -$1.81 |
| Equity (Book Value) | 1.92B |
| Book Value Per Share | 12.38 |
| Working Capital | 432.45M |
Cash Flow
In the last 12 months, operating cash flow was $287.56 million and capital expenditures -$31.01 million, giving a free cash flow of $256.55 million.
| Operating Cash Flow | 287.56M |
| Capital Expenditures | -31.01M |
| Free Cash Flow | 256.55M |
| FCF Per Share | $1.65 |
Margins
Gross margin is 66.50%, with operating and profit margins of 21.75% and 6.02%.
| Gross Margin | 66.50% |
| Operating Margin | 21.75% |
| Pretax Margin | 8.07% |
| Profit Margin | 6.02% |
| EBITDA Margin | 27.15% |
| EBIT Margin | 21.75% |
| FCF Margin | 21.03% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 69.57% |
| Buyback Yield | 0.66% |
| Shareholder Yield | 1.19% |
| Earnings Yield | 0.79% |
| FCF Yield | 2.77% |
Analyst Forecast
The average price target for Bio-Techne is $70.58, which is 18.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $70.58 |
| Price Target Difference | 18.46% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 7.49% |
| EPS Growth Forecast (5Y) | 44.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 11.52 and a Piotroski F-Score of 5.
| Altman Z-Score | 11.52 |
| Piotroski F-Score | 5 |